0001599298-24-000142.txt : 20240926 0001599298-24-000142.hdr.sgml : 20240926 20240925190016 ACCESSION NUMBER: 0001599298-24-000142 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240926 DATE AS OF CHANGE: 20240925 EFFECTIVENESS DATE: 20240926 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Summit Therapeutics Inc. CENTRAL INDEX KEY: 0001599298 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-525024 FILM NUMBER: 241325839 BUSINESS ADDRESS: STREET 1: 2882 SAND HILL ROAD STREET 2: SUITE 106 CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-460-8308 MAIL ADDRESS: STREET 1: 2882 SAND HILL ROAD STREET 2: SUITE 106 CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: Summit Therapeutics plc DATE OF NAME CHANGE: 20150219 FORMER COMPANY: FORMER CONFORMED NAME: Summit Corp plc DATE OF NAME CHANGE: 20140205 D 1 primary_doc.xml X0708 D LIVE 0001599298 Summit Therapeutics Inc. 601 Brickell Key Drive SUITE 1000 Miami FL FLORIDA 33131 305-203-2034 DELAWARE Summit Therapeutics plc Summit Corp plc Corporation true 2020 Robert Duggan 601 Brickell Key Drive Suite 1000 Miami FL FLORIDA 33131 Executive Officer Director Mahkam Zanganeh 601 Brickell Key Drive Suite 1000 Miami FL FLORIDA 33131 Executive Officer Director Manmeet Soni 601 Brickell Key Drive Suite 1000 Miami FL FLORIDA 33131 Executive Officer Director Kenneth Clark 601 Brickell Key Drive Suite 1000 Miami FL FLORIDA 33131 Director Robert Booth 601 Brickell Key Drive Suite 1000 Miami FL FLORIDA 33131 Director Alessandra Cesano 601 Brickell Key Drive Suite 1000 Miami FL FLORIDA 33131 Director Yu Xia 601 Brickell Key Drive Suite 1000 Miami FL FLORIDA 33131 Director Mostafa Ronaghi 601 Brickell Key Drive Suite 1000 Miami FL FLORIDA 33131 Director Jeff Huber 601 Brickell Key Drive Suite 1000 Miami FL FLORIDA 33131 Director Biotechnology Decline to Disclose 06b false 2024-09-11 false true false 0 234999889 234999889 0 false 17 0 0 75500000 $75.5 million of the proceeds from the offering were used to repay the outstanding principal balance on a promissory note issued by the Company to Robert Duggan, its CEO and Executive Chairman false Summit Therapeutics Inc. Manmeet Soni Manmeet Soni Chief Financial Officer 2024-09-25